Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.63 |
| ▸ | ACP1 | P24666 | 14/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 7/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.57 |
| ▸ | PTPRF | P10586 | 2/20 | 0.57 |
| ▸ | PTPRB | P23467 | 2/20 | 0.57 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172529 | 1.00 | PTPN1 (0.63) | PTPN1ACP1PTPN2ENPP2PTPRF | |
| SCHEMBL2174338 | 0.91 | MEN1 (0.64) | PTPN1ACP1ENPP2HSD17B3MEN1 | |
| SCHEMBL2174336 | 0.91 | MEN1 (0.64) | PTPN1ACP1ENPP2HSD17B3MEN1 | |
| SCHEMBL2173152 | 0.85 | PTPN1 (0.60) | PTPN1ACP1PTPN2ENPP2PTPRF | |
| SCHEMBL2173155 | 0.85 | PTPN1 (0.60) | PTPN1ACP1PTPN2ENPP2PTPRF | |
| SCHEMBL12406539 | 0.85 | PTPN1 (0.60) | PTPN1ACP1PTPN2ENPP2PTPRF | |
| SCHEMBL13754231 | 0.84 | HSD17B3 (0.61) | PTPN1ACP1ENPP2HSD17B3MEN1 | |
| SCHEMBL2176314 | 0.82 | HSD17B3 (0.58) | PTPN1ACP1ENPP2HSD17B3MEN1 | |
| SCHEMBL2176319 | 0.82 | HSD17B3 (0.58) | PTPN1ACP1ENPP2HSD17B3MEN1 | |
| SCHEMBL13754233 | 0.82 | HSD17B3 (0.54) | PTPN1ACP1PTPN2ENPP2PTPRF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | claimed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | claimed |
| EP-2254576-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | The Ohio State University Research Foundation (US) | 2010-12-01 | — | — | EP | claimed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | claimed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | claimed |
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2254576-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | The Ohio State University Research Foundation (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | AR, ESRRB, KLK3 | PTPN1 2303/4885ACP1 2351/4885PTPN2 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.